Lymphokine-activated killer cell

Content sourced from Wikipedia, licensed under CC BY-SA 3.0.

Lymphokine-activated killer (LAK) cells are a group of white blood cells that can be trained to kill cancer cells. They mostly include natural killer (NK) cells, natural killer T cells, and some T cells. When these cells are exposed to the protein IL-2 in the lab, they become very good at killing tumor cells, including some that NK cells can’t kill on their own. LAK cells can be grown in large numbers, which helps when they are used as cancer therapy.

LAK cells work like NK cells but are more powerful against tumors. They can target and lyse tumor cells at multiple sites and can attack some cells that don’t show typical signals that usually attract immune cells. Because they are made by stimulating with IL-2, they are not highly specific for a particular tumor type, which means they can hit a wide range of cancer cells but also can cause side effects.

In practice, LAK therapy has shown promise in laboratory and early clinical settings, especially for cancers that don’t respond well to standard treatments. However, a major challenge is safety. High doses of IL-2 are needed to activate LAK cells, and this can cause serious side effects like capillary leak syndrome, where fluids leak from small blood vessels and cause swelling and organ problems. Because LAK cells are not tightly targeted to tumors, their use can also affect healthy tissues.

Researchers are looking for ways to make LAK therapy safer and more effective. Dendritic cells and lactoferrin can boost LAK activity and help the immune system work better. Lactoferrin helps boost immune function from infancy to adulthood and is found in maternal milk and in certain white blood cells.

Scientists are also testing combination approaches. For example, combining LAK cells with Ad-p53 gene therapy may make tumor cells more visible to LAK cells. Another idea is using xanthohumol, a compound from hops, which can weaken a protein (TOPK) that helps tumors grow, thereby helping LAK cells kill cancer cells more effectively.

Some clinical studies have seen benefit from LAK therapy in people, such as reductions in malignant effusions and improved survival when IL-2 is used with LAK cells and other treatments. Yet the big hurdle remains safety and the lack of tumor-specific targeting, so ongoing research aims to make LAK-based treatments both safer and more precise.